ABVC BioPharma, Inc.
ABVC
$1.23
-$0.08-6.11%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -39,900.00% | 104.47% | -- | -- | -98.69% |
| Total Other Revenue | -- | -- | -- | -- | 92.28% |
| Total Revenue | -39,900.00% | 104.47% | -- | -- | -9.09% |
| Cost of Revenue | -- | -- | -- | -- | -100.00% |
| Gross Profit | -39,900.00% | 104.63% | -- | -- | 101.46% |
| SG&A Expenses | 221.66% | 196.02% | 141.45% | -76.03% | 122.93% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -107.69% | -130.99% | -- | -- | 3,891.67% |
| Total Operating Expenses | 191.90% | 180.84% | 134.85% | -75.59% | 46.67% |
| Operating Income | -298.80% | -276.80% | -166.83% | 75.58% | -46.88% |
| Income Before Tax | -378.64% | -164.22% | -99.36% | 67.75% | -51.71% |
| Income Tax Expenses | -- | 25.00% | 121.28% | -- | -100.00% |
| Earnings from Continuing Operations | -378.64% | -164.16% | -122.72% | 67.75% | -13.74% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 283.85% | -55.77% | -27.88% | 9.20% | -79.50% |
| Net Income | -387.00% | -215.73% | -139.52% | 70.29% | -90.87% |
| EBIT | -298.80% | -276.80% | -166.83% | 75.58% | -46.88% |
| EBITDA | -303.62% | -283.73% | -170.23% | 75.82% | -47.03% |
| EPS Basic | -160.11% | -68.55% | -56.01% | 80.66% | 3.48% |
| Normalized Basic EPS | -81.28% | -129.20% | -53.08% | 82.89% | -287.43% |
| EPS Diluted | -151.45% | -68.55% | -56.01% | 80.66% | 0.51% |
| Normalized Diluted EPS | -81.28% | -129.20% | -53.08% | 82.89% | -287.43% |
| Average Basic Shares Outstanding | 87.32% | 87.47% | 53.57% | 53.74% | 97.77% |
| Average Diluted Shares Outstanding | 87.32% | 87.47% | 53.57% | 53.74% | 97.77% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |